Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $14,650.20 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 32,556 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $0.45, for a total value of $14,650.20. Following the completion of the transaction, the director directly owned 622,579 shares in the company, valued at approximately $280,160.55. This represents a 4.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.46, for a total value of $12,741.08.
• On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total value of $38,808.96.
• On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $31,936.50.
• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total value of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total value of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total value of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $22,745.16.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $0.45 on Monday. The stock has a market capitalization of $21.87 million, a price-to-earnings ratio of -0.36 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $2.38. The business’s 50 day simple moving average is $0.74 and its 200-day simple moving average is $0.75.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on HOWL. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. Regal Investment Advisors LLC increased its position in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its position in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $48,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter valued at approximately $79,000. Finally, Bridgeway Capital Management LLC increased its position in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.